On the stock market since 2005, it operates in the world of health and science. It has 12 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $747K a year. A small number, but proof the product has real buyers.
It pays out $0.30 per share each year — regular cash for whoever holds the stock.
A loss of $3.0M against $747K in annual sales.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 28 sells against just 5 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, CYCCP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CYCCP is a high-risk stock — not yet profitable, and its future rides on its product catching on.